 |
|
|
| |
Consistency of Dolutegravir
Treatment Difference in HIV+ Treatment Naives at Week 96
|
| |
| |
Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Catherine Granier1, Naomi Givens1, Robert Cuffe2, Michael Aboud2, Louise Martin-Carpenter3, Kimberly Smith3, Clare Brennan4, Keith Pappa4, Brian Wynne4, Steve Almond5
1 R&D, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom;2 ViiV Healthcare, London, United Kingdom;3 ViiV Healthcare, Research Triangle Park, North Carolina, United States;4 GlaxoSmithKline, Research Triangle Park, North Carolina, United States;5 GlaxoSmithKline, Mississauga, Ontario, Canada
|
| |
|
|
|
|
|
